Serum Bone Turnover Markers May Be Involved in the Metastatic Potential of Lung Cancer Patients

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2009 Apr 18

PMID 19373566

Citations 19

Authors

Eleni M Karapanagiotou

Evangelos Terpos

Kalliopi D Dilana

Christina Alamara

Ioannis Gkiozos

Aris Polyzos

Kostas N Syrigos

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to investigate several bone markers in Non-Small Cell Lung (NSCLC) and Small Cell Lung (SCLC) patients experiencing or not secondary bony disease. Fasting serum levels of bone formation, bone resorption, and osteoclastogenesis markers were determined in 22 NSCLC patients with bone metastases, 18 without bone metastasis, and 28 SCLC patients. A total of 29 healthy volunteers were also included in the study. Decreased osteocalcin (OC) serum levels and increased osteopontin and ligand of the receptor of nuclear factor kB (RANKL) serum levels were detected in NCSLC patients with bone metastases while increased C-terminal cross-linking telopeptide of type I collagen and increased RANKL/OPG (osteoprotegerin) ratio were detected in SCLC patients. Increased serum levels of OPG were observed in all lung cancer patients. OPG may be actively involved in the development of lung cancer metastasis. Furthermore, OC, OPN, and RANKL in NSCLC and CTX and RANKL in SCLC patients may also have a broader role in the pathogenesis and spread of lung cancer. They also provide useful information in identifying the group of patients that may benefit from a more rigorous treatment.

Citing Articles

Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis.

Arakil N, Akhund S, Elaasser B, Mohammad K Biomedicines. 2024; 12(5).

PMID: 38791037 PMC: 11117796. DOI: 10.3390/biomedicines12051075.

Metabolic Health and Disease: A Role of Osteokines?.

Shimonty A, Bonewald L, Huot J Calcif Tissue Int. 2023; 113(1):21-38.

PMID: 37193929 DOI: 10.1007/s00223-023-01093-0.

Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value.

Chai X, Yinwang E, Wang Z, Wang Z, Xue Y, Li B Front Oncol. 2021; 11:692788.

PMID: 34722241 PMC: 8552022. DOI: 10.3389/fonc.2021.692788.

Establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancer.

Zhu Z, Yang G, Pang Z, Liang J, Wang W, Zhou Y World J Surg Oncol. 2021; 19(1):27.

PMID: 33487166 PMC: 7830744. DOI: 10.1186/s12957-021-02141-5.

High expression of USP22 predicts poor prognosis and advanced clinicopathological features in solid tumors: a meta-analysis.

Yang X, Zang H, Luo Y, Wu J, Fang Z, Zhu W Onco Targets Ther. 2018; 11:3035-3046.

PMID: 29872315 PMC: 5973323. DOI: 10.2147/OTT.S148662.

References

Kim K, Kim K, Sohn H, Lee U, Kim S, Lee W . The role of whole body bone scan in bronchogenic carcinoma. Yonsei Med J. 1984; 25(1):11-7. DOI: 10.3349/ymj.1984.25.1.11. View

Hofbauer L, Schoppet M . Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004; 292(4):490-5. DOI: 10.1001/jama.292.4.490. View

Terpos E, Szydlo R, Apperley J, Hatjiharissi E, Politou M, Meletis J . Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003; 102(3):1064-9. DOI: 10.1182/blood-2003-02-0380. View

Perez D, Powles T, Milan J, Gazet J, Ford H, McCready V . Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy. Lancet. 1983; 2(8350):613-6. DOI: 10.1016/s0140-6736(83)90692-x. View

Leeming D, Koizumi M, Byrjalsen I, Li B, Qvist P, Tanko L . The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2006; 15(1):32-8. DOI: 10.1158/1055-9965.EPI-05-0492. View

Coleman R . Conclusion: Bone markers in metastatic bone disease. Cancer Treat Rev. 2006; 32 Suppl 1:27-8. DOI: 10.1016/s0305-7372(06)80007-1. View

Mountzios G, Dimopoulos M, Bamias A, Papadopoulos G, Kastritis E, Syrigos K . Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol. 2007; 46(2):221-9. DOI: 10.1080/02841860600635870. View

Tanko L, Karsdal M, Christiansen C, Leeming D . Biochemical approach to the detection and monitoring of metastatic bone disease: What do we know and what questions need answers?. Cancer Metastasis Rev. 2006; 25(4):659-68. DOI: 10.1007/s10555-006-9024-0. View

Papotti M, Kalebic T, Volante M, Chiusa L, Bacillo E, Cappia S . Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. J Clin Oncol. 2006; 24(30):4818-24. DOI: 10.1200/JCO.2006.06.1952. View

10.

Terpos E, de la Fuente J, Szydlo R, Hatjiharissi E, Viniou N, Meletis J . Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer. 2003; 106(3):455-7. DOI: 10.1002/ijc.11247. View

11.

Cross S, Yang Z, Brown N, Balasubramanian S, Evans C, Woodward J . Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?. Int J Cancer. 2005; 118(8):1901-8. DOI: 10.1002/ijc.21606. View

12.

Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman R, Delmas P . Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 2000; 82(4):858-64. PMC: 2374389. DOI: 10.1054/bjoc.1999.1012. View

13.

ORegan A . The role of osteopontin in lung disease. Cytokine Growth Factor Rev. 2003; 14(6):479-88. DOI: 10.1016/s1359-6101(03)00055-8. View

14.

Takenaka K, Ishikawa S, Kawano Y, Yanagihara K, Miyahara R, Otake Y . Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. Eur J Cancer. 2004; 40(10):1617-23. DOI: 10.1016/j.ejca.2004.02.028. View

15.

Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P . Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer. 2004; 111(5):783-91. DOI: 10.1002/ijc.20314. View

16.

Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N . Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol. 2003; 163(5):2021-31. PMC: 1892410. DOI: 10.1016/s0002-9440(10)63560-2. View

17.

Theoleyre S, Wittrant Y, Tat S, Fortun Y, Redini F, Heymann D . The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004; 15(6):457-75. DOI: 10.1016/j.cytogfr.2004.06.004. View

18.

Arai Y, Takeuchi H, Oishi K, Yoshida O . Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer?. Prostate. 1992; 20(3):169-77. DOI: 10.1002/pros.2990200302. View

19.

Cho N, Hong K, Hong S, Kang S, Chung K, Cho S . MMP expression profiling in recurred stage IB lung cancer. Oncogene. 2003; 23(3):845-51. DOI: 10.1038/sj.onc.1207140. View

20.

Fedarko N, Jain A, Karadag A, Van Eman M, Fisher L . Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 2001; 7(12):4060-6. View